Alexion Pharmaceuticals Inc. (NASDAQ:ALXN)’s share price was up 3.1% during trading on Monday . The stock traded as high as $136.26 and last traded at $136.18, with a volume of 679,444 shares traded. The stock had previously closed at $132.13.

Several equities analysts have recently commented on ALXN shares. Morgan Stanley reissued an “overweight” rating on shares of Alexion Pharmaceuticals in a report on Wednesday, June 29th. Piper Jaffray Cos. reissued an “overweight” rating and issued a $185.00 target price on shares of Alexion Pharmaceuticals in a report on Tuesday, August 16th. Citigroup Inc. raised shares of Alexion Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $154.00 target price on the stock in a report on Monday, June 27th. Royal Bank Of Canada started coverage on shares of Alexion Pharmaceuticals in a report on Tuesday, July 12th. They issued an “outperform” rating and a $188.00 target price on the stock. Finally, Jefferies Group reissued a “hold” rating and issued a $140.00 target price (down previously from $159.00) on shares of Alexion Pharmaceuticals in a report on Monday, July 25th. Seven research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $182.98.

The firm has a market capitalization of $30.81 billion and a P/E ratio of 345.18. The firm has a 50 day moving average price of $129.82 and a 200-day moving average price of $137.86.

Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its quarterly earnings data on Thursday, July 28th. The biopharmaceutical company reported $1.13 earnings per share for the quarter, missing analysts’ consensus estimates of $1.17 by $0.04. The business earned $753 million during the quarter, compared to the consensus estimate of $743.18 million. During the same quarter in the prior year, the firm earned $1.44 EPS. The business’s quarterly revenue was up 18.4% compared to the same quarter last year. On average, equities research analysts anticipate that Alexion Pharmaceuticals Inc. will post $4.65 EPS for the current year.

In other news, CEO David Hallal sold 332 shares of Alexion Pharmaceuticals stock in a transaction on Monday, August 8th. The stock was sold at an average price of $137.14, for a total transaction of $45,530.48. Following the transaction, the chief executive officer now owns 189,266 shares in the company, valued at approximately $25,955,939.24. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, SVP Heidi L. Wagner sold 222 shares of Alexion Pharmaceuticals stock in a transaction on Monday, August 8th. The stock was sold at an average price of $137.14, for a total value of $30,445.08. Following the transaction, the senior vice president now owns 32,115 shares in the company, valued at approximately $4,404,251.10. The disclosure for this sale can be found here.

Other hedge funds and institutional investors recently bought and sold shares of the company. I.G. Investment Management LTD. raised its position in Alexion Pharmaceuticals by 4.6% in the fourth quarter. I.G. Investment Management LTD. now owns 31,750 shares of the biopharmaceutical company’s stock valued at $6,056,000 after buying an additional 1,410 shares in the last quarter. BNP Paribas Arbitrage SA raised its position in Alexion Pharmaceuticals by 563.8% in the fourth quarter. BNP Paribas Arbitrage SA now owns 113,751 shares of the biopharmaceutical company’s stock valued at $21,698,000 after buying an additional 96,615 shares in the last quarter. Dimensional Fund Advisors LP raised its position in Alexion Pharmaceuticals by 2.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 289,785 shares of the biopharmaceutical company’s stock valued at $55,277,000 after buying an additional 6,189 shares in the last quarter. KBC Group NV raised its position in Alexion Pharmaceuticals by 82.0% in the fourth quarter. KBC Group NV now owns 40,298 shares of the biopharmaceutical company’s stock valued at $7,687,000 after buying an additional 18,160 shares in the last quarter. Finally, American International Group Inc. raised its position in Alexion Pharmaceuticals by 1.2% in the fourth quarter. American International Group Inc. now owns 98,141 shares of the biopharmaceutical company’s stock valued at $18,720,000 after buying an additional 1,203 shares in the last quarter.

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. The Company operates through innovation, development and commercialization of life-transforming therapeutic products segment. The Company’s marketed products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.